Options in Basal Insulin—Basaglar® (Insulin Glargine Injection)
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly USA, LLC

This program will discuss an FDA-approved insulin glargine option from the Boehringer Ingelheim and Eli Lilly and Company Alliance. The presentation will provide information regarding the Basaglar clinical profile, as well as dosing and administration. Attendees will have the opportunity to ask the faculty questions about the data presented.

Presenter: Thomas C. Blevins, MD
Endocrinologist
Texas Diabetes & Endocrinology
Dallas, TX

Location: Product Theater 1 (Booth 154)

The Role of a Once-Weekly GLP-1 RA Therapy in Improving Glucose Control
Sponsored by AstraZeneca

This presentation will demonstrate how glucose profiles differ amongst patients with type 2 diabetes and the opportunity to manage glucose fluctuations. The content includes a review of a study that evaluated a specific glucagon-like-peptide-1 receptor agonist (GLP-1 RA) therapy using continuous glucose monitoring (CGM) to determine its effect on 24-hour glucose control in patients with type 2 diabetes. Additionally, efficacy of this Once-Weekly GLP-1RA proven in a series of clinical trials that showed both short- and long-term efficacy will also be presented. Concluding the program will be information on the proper device preparation and administration of this Once-Weekly GLP-1 RA therapy.

Presenter: Helena W. Rodbard, MD, FACP, FACE
Endocrine and Metabolic Consultants
Rockville, MD

Location: Product Theater 2 (Booth 1254)
2:45 p.m.–3:30 p.m.

Toujeo® (Insulin Glargine Injection 300 Units/mL)—A Once Daily Basal Insulin—Clinical Overview and Features
Sponsored by Sanofi

Toujeo® (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo®, including the pharmacologic profile and data from 4 EDITION clinical trials carried out in a range of adult patients with diabetes. Please see full Prescribing Information for Toujeo® at the Sanofi booth 919.

Presenters:  
Steven V. Edelman, MD  
Director, Taking Control of Your Diabetes (TCOYD®)  
Clinical Professor of Medicine  
University of California, San Diego  
San Diego, CA

William H. Polonsky, PhD, CDE  
President, Behavioral Diabetes Institute  
Associate Clinical Professor in Psychiatry  
University of California, San Diego  
San Diego, CA

Bruce W. Bode, MD, FACE  
Clinician  
Atlanta Diabetes Associates  
Atlanta, GA

Deborah A. Hinnen, RN, APN, BC-ADM, CDE, FAAN, FAADE  
Clinician and Diabetes Educator  
Memorial Hospital  
University of Colorado Health  
Colorado Springs, CO

Location:  
Product Theater 1 (Booth 154)

2:45 p.m.–3:30 p.m.

A Once-Daily Basal Insulin Option for the Primary Care Management of Diabetes
Sponsored by Novo Nordisk

Discuss insulin therapy in optimizing glycemic control and long-acting basal insulin for adult patients with type 2 diabetes. Examine the efficacy and safety data of a long-acting basal insulin therapy. Describe a treatment approach that can be initiated in your adult patients with diabetes.

Presenter:  
Pablo F. Mora, MD, MSc, FACE, CDE  
Endocrinologist  
Diabetes America  
Plano, TX

Clinical Associate Professor  
Division of Endocrinology  
University of Texas Southwestern Medical Center  
Dallas, TX

Location:  
Product Theater 2 (Booth 1254)
SUNDAY, JUNE 12

10:15 a.m.–11:00 a.m.

The Importance of Utilizing a Comprehensive Approach When Managing Patients with T2DM

*Sponsored by Sanofi*

T2DM is a complex, progressive disease. As the number of patients with diabetes increases, it is critical to take a closer look at the ongoing challenges of getting patients to glycemic goal despite the availability of medications and detailed treatment guidelines. In this presentation, we will take a closer look at the effects of hyperglycemia prior to diabetes diagnosis, the importance of achieving individualized glycemic goals, the current diabetes treatment landscape, and finally, the potential of multifactorial approaches to treatment.

**Presenter:** Lawrence Blonde, MD, FACP, FACE  
Director, Ochsner Diabetes Clinical Research Unit  
The Frank Riddick Diabetes Institute  
New Orleans, LA

**Location:** Product Theater 1 (Booth 154)

10:15 a.m.–11:00 a.m.

Repatha (Evolocumab)—Product Overview

*Sponsored by Amgen*

**Presenter:**

**Location:** Product Theater 2 (Booth 1254)

12:30 p.m.–1:30 p.m.

Examining Options to Go Further in the Treatment of Type 2 Diabetes

*Sponsored by Janssen Pharmaceuticals, Inc.*

This program will cover the following topics regarding a sodium-glucose co-transporter (SGLT-2) inhibitor: the role of the kidney in regulation of hyperglycemia in T2DM; the mechanism of action-mediated inhibition of SGLT-2 in the proximal convoluted tubule of the kidney; key efficacy and safety data from active-controlled clinical trials; important safety information; and a question and answer session. This program is not certified for continuing medical education.

**Presenters:**  
Carol H. Wysham, MD  
Clinical Associate Professor of Medicine  
University of Washington  
Spokane, WA

Matthew Budoff, MD  
Professor of Medicine  
University of California, Los Angeles  
Torrance, CA

John E. Anderson, MD  
Past President, Medicine & Science  
American Diabetes Association  
The Frist Clinic  
Nashville, TN

**Location:** Product Theater 1 (Booth 154)
12:30 p.m.–1:30 p.m.

**SGLT-2 Inhibition—A Glucuretic Treatment Option for Your Adult Patients With Type 2 Diabetes**

*Supported by AstraZeneca*

The kidney has an important role in the body's regulation of glucose. In patients with type 2 diabetes, the adaptive mechanism to reabsorb glucose in the kidney is thought to become maladaptive. This program will focus on the role of sodium-glucose cotransporter-2 (SGLT-2) inhibition to reduce reabsorption of filtered glucose, lower the renal threshold for glucose, and increase urinary glucose excretion. In addition, the clinical efficacy, safety, and use of an SGLT-2 inhibitor for patients with type 2 diabetes will be reviewed.

**Presenter:** Serge Jabbour, MD, FACP, FACE  
Professor of Medicine  
Director, Division of Endocrinology, Diabetes, & Metabolic Disease  
Sidney Kimmel Medical College at Thomas Jefferson University  
Philadelphia, PA

**Location:** Product Theater 2 (Booth 1254)

3:00 p.m.–3:45 p.m.

**Toujeo® (Insulin Glargine Injection 300 Units/mL)—A Once Daily Basal Insulin—Clinical Overview and Features**

*Supported by Sanofi*

Toujeo® (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo® and to review case studies of patients staring Toujeo®. Pharmacologic features of Toujeo® and data from the EDITION clinical trials program will also be presented. Please see full Prescribing Information for Toujeo® at the Sanofi booth 919.

**Presenters:** Jeremy Pettus, MD  
University of California, San Diego  
La Jolla, CA  
Timothy Gilbert

**Location:** Product Theater 1 (Booth 154)

3:00 p.m.–3:45 p.m.

**A Treatment Option for Patients Who Are Severely Insulin Resistant**

*Supported by Lilly USA, LLC*

The program is about a concentrated human insulin indicated to improve glycemic control in patients with diabetes requiring >200 units of insulin a day. Hear about the product profile, patients who may benefit from it, clinical results and titration-to-target algorithms, and the dedicated injection device.

**Presenter:** Robert C. Hood, MD, FRCPC, FACE  
Director, Endocrine Clinic of Southeast Texas  
Beaumont, TX

**Location:** Product Theater 2 (Booth 1254)
The Efficacy Mirage in Type 2 Diabetes—Why Do Clinical Trial Results Disappear in Real-World Practice?
*Sponsored by Intarcia Therapeutics, Inc.*

Since 2005, nearly 40 new treatments have been approved for type 2 diabetes (T2D) with some of these agents showing impressive clinical trial efficacy. Despite this, less than half of the patient population achieves HbA1c goal, and morbidity and mortality rates are at an alarming level. Recent data have demonstrated that outcomes in the real-world fall far short of the efficacy seen in clinical trials. Adherence and persistence are key drivers behind this disconnect with current agents delivering adherence rates of less than 50% and persistence rates of less than 25% over a year.

This presentation will discuss the current state of diabetes and will challenge attendees to think differently about management approaches so that in the future we can finally deliver the improved patient outcomes that we have not been able to recognize with current therapies.

**Presenters:**
Steven V. Edelman, MD  
Director, Taking Control of Your Diabetes (TCOYD®)  
Clinical Professor of Medicine  
University of California, San Diego  
San Diego, CA

William H. Polonsky, PhD, CDE  
President, Behavioral Diabetes Institute  
Associate Clinical Professor in Psychiatry  
University of California, San Diego  
San Diego, CA

**Location:**  
Product Theater 1 (Booth 154)

Rationale for an Oral Treatment for Type 2 Diabetes that Targets the Incretin Hormones
*Sponsored by Merck*

Understand the incretin effect and its impact on islet function and hepatic glucose production in T2DM.
Discuss an oral treatment that targets the incretin hormones and helps to improve glycemic control in T2DM.

**Presenter:**  
Helena W. Rodbard, MD, FACP, FACE  
Endocrine and Metabolic Consultants  
Past President, American Association of Clinical Endocrinologists  
Past President, American College of Endocrinology  
Rockville, MD

**Location:**  
Product Theater 2 (Booth 1254)